Published in Pharm Res on August 01, 2004
Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res (2012) 3.29
Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res (2008) 1.17
Mechanisms of peptide amphiphile internalization by SJSA-1 cells in vitro. Biochemistry (2009) 1.06
Cerebrocortical beta activity in overweight humans responds to insulin detemir. PLoS One (2007) 1.04
Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart. Pharm Res (2015) 1.02
Design of non-standard insulin analogs for the treatment of diabetes mellitus. Curr Diab Rep (2012) 1.00
Brain meets body: the blood-brain barrier as an endocrine interface. Endocrinology (2012) 0.98
Engineering of therapeutic proteins production in Escherichia coli. Curr Pharm Biotechnol (2011) 0.97
The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin. Diabetes Care (2012) 0.97
Degludec insulin: A novel basal insulin. Indian J Endocrinol Metab (2011) 0.97
Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates. Proc Natl Acad Sci U S A (2015) 0.95
Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care (2012) 0.95
Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem (2009) 0.94
Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes. Diabetes Care (2011) 0.92
Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs. Drug Healthc Patient Saf (2010) 0.91
Cell factories for insulin production. Microb Cell Fact (2014) 0.88
Insulin detemir is not transported across the blood-brain barrier. Peptides (2010) 0.88
Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial. Diabet Med (2013) 0.86
Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering. Ann N Y Acad Sci (2012) 0.82
Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog. Diabetes (2014) 0.82
Peptide lipidation stabilizes structure to enhance biological function. Mol Metab (2013) 0.81
Insulin detemir in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag (2006) 0.81
Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action. PLoS One (2014) 0.81
Tuning the activity of a short arg-trp antimicrobial Peptide by lipidation of a C- or N-terminal lysine side-chain. ACS Med Chem Lett (2012) 0.80
Insulin detemir for the treatment of obese patients with type 2 diabetes. Diabetes Metab Syndr Obes (2012) 0.79
Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes. Patient Prefer Adherence (2008) 0.79
Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding. Theranostics (2016) 0.79
Pursuit of a perfect insulin. Nat Rev Drug Discov (2016) 0.78
Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment. Bioconjug Chem (2015) 0.78
Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia. Vasc Health Risk Manag (2009) 0.78
Acylation of Glucagon-like peptide-2: interaction with lipid membranes and in vitro intestinal permeability. PLoS One (2014) 0.77
A framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues. Carcinogenesis (2015) 0.77
Biophysical optimization of a therapeutic protein by nonstandard mutagenesis: studies of an iodo-insulin derivative. J Biol Chem (2014) 0.77
Insulin detemir enhances proglucagon gene expression in the intestinal L cells via stimulating β-catenin and CREB activities. Am J Physiol Endocrinol Metab (2012) 0.77
Site-specific fatty acid-conjugation to prolong protein half-life in vivo. J Control Release (2013) 0.77
Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics. Diabetes Metab Syndr Obes (2010) 0.76
Future of newer basal insulin. Indian J Endocrinol Metab (2013) 0.76
Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery. Proc Natl Acad Sci U S A (2016) 0.76
Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring. Diabetes Metab Syndr Obes (2011) 0.76
Design of Insulin-Loaded Nanoparticles Enabled by Multistep Control of Nanoprecipitation and Zinc Chelation. ACS Appl Mater Interfaces (2017) 0.75
Novel lipidized analogs of prolactin-releasing peptide have prolonged half-lives and exert anti-obesity effects after peripheral administration. Int J Obes (Lond) (2015) 0.75
Replacement of neutral protamine Hagedorn insulin with the long-acting insulin analogue, detemir, improves glycemic control without weight gain in basal-bolus insulin therapy in Japanese patients with type 1 diabetes. J Diabetes Investig (2011) 0.75
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab (2016) 0.75
Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years. Diabetes Ther (2016) 0.75
Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations. Drug Des Devel Ther (2016) 0.75
Effects of Selected Anionic β-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats. J Drug Deliv (2011) 0.75
Soluble insulin analogs combining rapid- and long-acting hypoglycemic properties - From an efficient E. coli expression system to a pharmaceutical formulation. PLoS One (2017) 0.75
A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use. Clin Pharmacokinet (2016) 0.75
A current perspective on applications of macrocyclic-peptide-based high-affinity ligands. Biopolymers (2016) 0.75
Treatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog. Clin Med Insights Endocrinol Diabetes (2010) 0.75
United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes. Drug Des Devel Ther (2017) 0.75
Controlled release of biologics for the treatment of type 2 diabetes. J Control Release (2015) 0.75
Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab (2016) 0.75
Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med (2007) 11.62
Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res (2012) 3.29
Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes (2007) 2.24
The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes (2003) 2.16
Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors. J Med Chem (2003) 1.98
A novel high-affinity peptide antagonist to the insulin receptor. Biochem Biophys Res Commun (2008) 1.75
The BIGTT test: a novel test for simultaneous measurement of pancreatic beta-cell function, insulin sensitivity, and glucose tolerance. Diabetes Care (2007) 1.60
GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol (2003) 1.23
Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother (2006) 1.16
Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart. Pharm Res (2015) 1.02
Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks. Proc Natl Acad Sci U S A (2003) 0.98
Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry (2013) 0.96
Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab (2006) 0.96
Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both? Diabetes (2003) 0.94
Structural and biological properties of the Drosophila insulin-like peptide 5 show evolutionary conservation. J Biol Chem (2010) 0.94
Insulins with built-in glucose sensors for glucose responsive insulin release. J Pept Sci (2005) 0.90
Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake. Diabetes (2002) 0.89
Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives. Pharm Res (2006) 0.88
Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV. Eur J Pharmacol (2005) 0.86
Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism (2003) 0.86
Reversible insulin self-assembly under carbohydrate control. J Am Chem Soc (2005) 0.86
Insulin's 85th anniversary--An enduring medical miracle. Diabetes Res Clin Pract (2007) 0.85
Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight. J Clin Endocrinol Metab (2005) 0.85
Bioequivalence of topical formulations in humans: evaluation by dermal microdialysis sampling and the dermatopharmacokinetic method. J Invest Dermatol (2006) 0.85
Evaluation of different methods for assessment of insulin sensitivity in Gottingen minipigs: introduction of a new, simpler method. Am J Physiol Regul Integr Comp Physiol (2009) 0.85
Backbone cyclic insulin. J Pept Sci (2010) 0.83
Chamber-dependent expression of brain natriuretic peptide and its mRNA in normal and diabetic pig heart. Hypertension (2002) 0.83
KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. J Clin Endocrinol Metab (2008) 0.83
Mode of transcapillary transport of insulin and insulin analog NN304 in dog hindlimb: evidence for passive diffusion. Diabetes (2002) 0.82
Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. J Pharmacokinet Pharmacodyn (2003) 0.82
Insulin analog with additional disulfide bond has increased stability and preserved activity. Protein Sci (2013) 0.81
Insulin secretion after short- and long-term low-grade free fatty acid infusion in men with increased risk of developing type 2 diabetes. Metabolism (2003) 0.81
Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced beta-cell mass. Exp Diabesity Res (2003) 0.81
Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. J Pharm Pharmacol (2012) 0.81
Association between positive patch tests to epoxy resin and fragrance mix I ingredients. Contact Dermatitis (2009) 0.78
Crystallographic and solution studies of N-lithocholyl insulin: a new generation of prolonged-acting human insulins. Biochemistry (2004) 0.78
In nondiabetic, human immunodeficiency virus-infected patients with lipodystrophy, hepatic insulin extraction and posthepatic insulin clearance rate are decreased in proportion to insulin resistance. Metabolism (2005) 0.78
Identification of anchor points for chemical modification of a small cysteine-rich protein by using a cysteine scan. Chembiochem (2011) 0.78
[Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes]. Ugeskr Laeger (2007) 0.77
Insulin aspart: promising early results borne out in clinical practice. Expert Opin Pharmacother (2002) 0.76
Topical Calcineurin Inhibitors, Topical Glucocorticoids and Cancer in Children: A Nationwide Study. Acta Derm Venereol (2016) 0.75
Influence of a detergent on skin response to methyldibromo glutaronitrile in sensitized individuals. Contact Dermatitis (2004) 0.75
Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Clin Endocrinol (Oxf) (2005) 0.75
The nickel dose-response relationship by filaggrin genotype (FLG). Contact Dermatitis (2014) 0.75
125I used for labelling of proteins in an absorption model changes the absorption rate of insulin aspart. Int J Pharm (2006) 0.75
Mechanism of action in dogs of slow-acting insulin analog O346. J Clin Endocrinol Metab (2003) 0.75
Combined effects of irritants and allergens. Synergistic effects of nickel and sodium lauryl sulfate in nickel- sensitized individuals. Contact Dermatitis (2002) 0.75